---
title: "Bio-Path Holdings (BPTH) news: reverse split and delisting"
url: "https://aibio.space/companies/bio-path/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "BPTH reverse split, delisting and offering news: Bio-Path cancels planned reverse split and approves treasury plan. Bio-Path Holdings, Inc."
---

BPTH Bio-Path Holdings, Inc. OTC · United States

# Bio-Path Holdings (BPTH) news BPTH reverse split, delisting and offering news

Financings · 2026-07-16

## [Bio-Path sells small Regulation A lots and hires a strategic advisor](https://aibio.space/news/bio-path-sells-small-regulation-lots-hires-strategic-advisor/)

Bio-Path reports two small share sales under its Regulation A offering and an advisory engagement to find a buyer, partner or licensor.

## Latest Bio-Path Holdings news

1. 2026-05-26 Company Updates [Bio-Path cancels planned reverse split and approves treasury plan](https://aibio.space/news/bio-path-cancels-planned-reverse-split-approves-treasury-plan/) The company canceled a previously approved 1-30 reverse split and its board approved a digital asset treasury and a share of a court judgment held by its chief executive.
2. 2025-07-11 Listings [Nasdaq files Form 25 to remove Bio-Path Holdings common stock from listing](https://aibio.space/news/nasdaq-files-form-25-remove-bio-path-holdings-common-stock-listing/) Nasdaq Stock Market LLC filed a Form 25 notification dated July 11, 2025 to strike Bio-Path Holdings' common stock from listing and registration. The notice cites Exchange Act Rule 12d2-2(b), which covers removals the exchange initiates, and it does not give the reason.

## Bio-Path Holdings at a glance

- **Ticker**: BPTH

- **Listing**: OTC

- **Country**: United States

- **Cash, Mar 31, 2026**: $12,000

### Related companies

- [Aspira Women's Health](https://aibio.space/companies/aspira-women-s-health/) OTC: AWHL
- [ThermoGenesis Holdings](https://aibio.space/companies/thermogenesis/) OTC: THMO
- [Q32 Bio](https://aibio.space/companies/q32-bio/) NASDAQ: QTTB
- [Humacyte](https://aibio.space/companies/humacyte/) NASDAQ: HUMA
- [Sana Biotechnology](https://aibio.space/companies/sana-biotechnology/) NASDAQ: SANA
- [Biomolecular Life Holdings](https://aibio.space/companies/biomolecular-life/) OTC: BIOM
- [GridAI Technologies](https://aibio.space/companies/gridai-technologies/) NASDAQ: GRDX
- [Vor Biopharma](https://aibio.space/companies/vor-biopharma/) NASDAQ: VOR

### Also on OTC

- [Glucose Health](https://aibio.space/companies/glucose-health/) GLUC
- [CapForce](https://aibio.space/companies/capforce/) CFOR
- [ZyVersa Therapeutics](https://aibio.space/companies/zyversa-therapeutics/) ZVSA
- [SQZ Biotechnologies](https://aibio.space/companies/sqz-biotechnologies/) SQZB
- [Vaccinex](https://aibio.space/companies/vaccinex/) VCNX
- [GlobeStar Therapeutics](https://aibio.space/companies/globestar-therapeutics/) GSTC

## Bio-Path Holdings annual financials

| Line | FY2024 | FY2023 |
|---|---|---|
| Research and development | [$7.3 million](https://www.sec.gov/Archives/edgar/data/1133818/000155837025003837/) | [$11.6 million](https://www.sec.gov/Archives/edgar/data/1133818/000155837025003837/) |
| Net income (loss) | [-$9.9 million](https://www.sec.gov/Archives/edgar/data/1133818/000155837025003837/) | [-$16.1 million](https://www.sec.gov/Archives/edgar/data/1133818/000155837025003837/) |
| Cash from operations | [-$10.6 million](https://www.sec.gov/Archives/edgar/data/1133818/000155837025003837/) | [-$11.5 million](https://www.sec.gov/Archives/edgar/data/1133818/000155837025003837/) |
| Cash and equivalents | [$1.2 million](https://www.sec.gov/Archives/edgar/data/1133818/000166357726000156/) | [$1.1 million](https://www.sec.gov/Archives/edgar/data/1133818/000166357726000009/) |

Latest balance sheet, Mar 31, 2026 (10-Q): cash and equivalents $12,000.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Bio-Path Holdings

Did Bio-Path Holdings do a reverse stock split?

Our latest story on this, dated May 26, 2026: "Bio-Path cancels planned reverse split and approves treasury plan". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/bio-path-cancels-planned-reverse-split-approves-treasury-plan/).

Was Bio-Path Holdings delisted?

Our latest story on this, dated Jul 11, 2025: "Nasdaq files Form 25 to remove Bio-Path Holdings common stock from listing". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nasdaq-files-form-25-remove-bio-path-holdings-common-stock-listing/).

Has Bio-Path Holdings raised money recently?

Our latest story on this, dated Jul 16, 2026: "Bio-Path sells small Regulation A lots and hires a strategic advisor". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/bio-path-sells-small-regulation-lots-hires-strategic-advisor/).

What is the ticker symbol of Bio-Path Holdings?

Bio-Path Holdings, Inc. trades under the ticker BPTH on OTC.

Where is Bio-Path Holdings listed?

Bio-Path Holdings, Inc. is listed on OTC.

What is the SEC CIK of Bio-Path Holdings?

The SEC Central Index Key (CIK) for Bio-Path Holdings, Inc. is 1133818. Its filings are on SEC EDGAR.

How many shares does Bio-Path Holdings have outstanding?

50,297,451 shares as of 2026-05-20, per the cover page of its 10-Q filed 2026-05-20.

Which country or territory is Bio-Path Holdings listed under?

Our directory records Bio-Path Holdings, Inc. under United States.

What does Bio-Path Holdings do?

Our directory classifies Bio-Path Holdings, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Bio-Path Holdings?

The ISIN recorded for Bio-Path Holdings, Inc. is US09057N4097.

Does aibio.space cover Bio-Path Holdings?

aibio.space lists Bio-Path Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Bio-Path Holdings incorporated?

SEC records list its state or country of incorporation as WY.

Is Bio-Path Holdings profitable?

Bio-Path Holdings, Inc. reported a net loss of $9.9 million for the fiscal year ended Dec 31, 2024, and used $10.6 million of cash in operations, per its annual report to the SEC.

How much does Bio-Path Holdings spend on research and development?

$7.3 million in the fiscal year ended Dec 31, 2024, per its annual report.

How much cash does Bio-Path Holdings have?

$12,000 in cash at Mar 31, 2026, per its 10-Q.

## Investor discussion: Bio-Path Holdings

Members talk about Bio-Path Holdings (BPTH). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Bio-Path Holdings, newest first. Each line links the filing it comes from.

1. 2026-05-26 Listings Reported a reverse stock split. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1133818/000166357726000170/bpth_8k052626.htm)
2. 2026-05-22 Listings Filed to end its SEC reporting. SEC Form 15-12G. [Source](https://www.sec.gov/Archives/edgar/data/1133818/000166357726000165/bpth_form15.htm)
3. 2026-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1133818/000166357726000143/bpth_nt10q.htm)
4. 2026-02-24 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.01,5.03,7.01,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1133818/000166357726000046/bpth_8k022426.htm)
5. 2025-11-17 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1133818/000166357725000332/nt_10q.htm)
6. 2025-11-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 8-K (Items 5.02,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1133818/000166357725000317/bpth_8k110425.htm)
7. 2025-08-13 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1133818/000110465925077665/tm2523449d1_8k.htm)
8. 2025-07-11 Listings Filed to remove its shares from exchange listing. SEC Form 25-NSE. [Source](https://www.sec.gov/Archives/edgar/data/1133818/000135445725000650/xslF25X02/primary_doc.xml)
9. 2025-03-27 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1133818/000155837025003837/bpth-20241231x10k.htm)
10. 2025-02-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1133818/000155837025001051/bpth-20250214x8k.htm)
11. 2025-01-21 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1133818/000110465925004576/bpth-20240930xs1.htm)
12. 2024-12-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1133818/000110465924128517/tm2431094d1_8k.htm)
13. 2024-11-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1133818/000110465924122574/tm2429498d1_8k.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:BPTH on TradingView](https://www.tradingview.com/symbols/OTC-BPTH/).

## SEC filings and registration

- **SEC name**: Bio-Path Holdings, Inc.

- **CIK**: 1133818

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: BPTH (OTC)

- **State or country of incorporation**: WY

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 4710 BELLAIRE BOULEVARD, BELLAIRE, TX, 77401

- **Phone**: (832) 742-1357

- **Shares outstanding**: 50,297,451 as of 2026-05-20 (10-Q filed 2026-05-20)

- **Former names**: BIO-PATH HOLDINGS INC; OGDEN GOLF CO CORP

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1133818/000166357726000218/bpth_8k071626.htm) filed 2026-07-16
- [8-K](https://www.sec.gov/Archives/edgar/data/1133818/000166357726000170/bpth_8k052626.htm) filed 2026-05-26
- [10-Q](https://www.sec.gov/Archives/edgar/data/1133818/000166357726000156/bpth_10q1033126.htm) filed 2026-05-20
- [8-K](https://www.sec.gov/Archives/edgar/data/1133818/000166357726000064/bpth_8k031926.htm) filed 2026-03-20
- [8-K](https://www.sec.gov/Archives/edgar/data/1133818/000166357726000046/bpth_8k022426.htm) filed 2026-02-24
- [10-Q](https://www.sec.gov/Archives/edgar/data/1133818/000166357726000009/bpth10q_093025.htm) filed 2026-01-13
- [8-K](https://www.sec.gov/Archives/edgar/data/1133818/000166357725000317/bpth_8k110425.htm) filed 2025-11-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1133818/000166357725000303/bpth_8k102225.htm) filed 2025-10-29

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001133818), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Bio-Path Holdings, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker BPTH, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Bio-Path Holdings, Inc.

- **Ticker**: BPTH

- **Listing**: OTC

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US09057N4097

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-BPTH/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/bio-path/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Bio-Path Holdings (BPTH) news: reverse split and delisting", 2026-10-31, https://aibio.space/companies/bio-path/